Hemogenyx Pharmaceuticals PLC Announces Final Results

Arizona Tribune - Hemogenyx Pharmaceuticals PLC Announces Final Results

Hemogenyx Pharmaceuticals PLC Announces Final Results

LONDON, UNITED KINGDOM / ACCESS Newswire / April 28, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2024. The Annual Report is available to view on the Company's website at https://hemogenyx.com/.

Text size:

Key Highlights

The Company commenced Phase I clinical trials of its HG-CT-1 product candidate.
Continuing development of Chimeric Bait Receptor antiviral/biodefence platform, which gained attention at major conferences.
Successfully raised £3.9 million (before expenses) through the allotment and issue of new ordinary shares during the year ended 31 December 2024, and a further £1.3 million in early 2025.

Fuller details of these developments are contained in the full, unedited text of the final results for the year ended 31 December 2024 below.

http://www.rns-pdf.londonstockexchange.com/rns/3187G_1-2025-4-25.pdf

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	[email protected]
Peter Redmond, Director	[email protected]
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on ACCESS Newswire

Th.Gonzalez--AT

BCC	0.01%	75.88	$
JRI	-0.1%	13.5	$
GSK	1.13%	49.34	$
CMSC	0.17%	23.34	$
RBGPF	0.5%	82.01	$
BCE	0.02%	23.34	$
RYCEF	-2.12%	14.64	$
CMSD	0.06%	23.38	$
RIO	1.71%	77.32	$
RELX	0%	40.83	$
BTI	0.59%	57.635	$
VOD	0.78%	12.8	$
BP	1.66%	34.33	$
NGG	1.47%	76.93	$
SCS	0.12%	16.14	$
AZN	-0.22%	91.15	$

Arizona Tribune - Hemogenyx Pharmaceuticals PLC Announces Final Results

Hemogenyx Pharmaceuticals PLC Announces Final Results

Featured

Romania journalists back media outlet that sparked graft protests

Rob Reiner's son awaiting court appearance on murder charges

Ten-year-old girl, Holocaust survivors among Bondi Beach dead

Myanmar junta seeks to prosecute hundreds for election 'disruption'